Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 481-485

  Bolaños Meade, Javier ^a   Wu, Juan ^b   Logan, Brent R ^c   Levine, John E ^d   Ho, Vincent T ^e   Alousi, Amin M ^f   Weisdorf, Daniel J ^g   Luznik, Leo ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b EMMES CORPORATION   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Chronic graft versus host disease; Flow cytometry

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; DENILEUKIN DIFTITOX; ETANERCEPT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTE SUBSETS; BONE MARROW TRANSPLANTATION; DIPHTHERIA TOXIN; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PENTOSTATIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84873591805     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.12.003     Document Type: Article

References (13)

1. Bolaños-Meade J., Vogelsang G.B. Acute graft-versus-host disease. Clin Adv Hematol Oncol 2004, 2:672-682.
2. De Serres S.A., Sayegh M.H., Najafian N. Immunosuppressive drugs and Tregs: a critical evaluation. Clin J Am Soc Nephrol 2009, 4:1661-1669.
3. high regulatory T cells. Blood 2004, 103:2410-2416.
4. + T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood 2004, 103:1140-1146.
5. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
6. Bolaños-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005, 23:2661-2668.
7. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:680-687.
8. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
9. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998, 22:61-65.
10. Grogan B.M., Tabellini L., Storer B., et al. Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1121-1132.
11. Bosch M., Khan F.M., Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012, 19:324-335.
12. + regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006, 16:150-159.
13. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.